KRAS and hematopoietic and lymphoid cell neoplasm: While loss of wild-type Kras was shown to promote activation of all RAS isoforms in a leukaemia model37, loss of wild-type Nras did not alter the tumorigenic behaviour of mutant NRAS-G12D in a hematopoietic cancer model38.